Please assess the completion status of the following clinical trial:

Trial Title: OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who presented or were admitted to hospital with:~  1. Signs and symptoms of AMI~ 2. Were able to randomize within 12 hours of symptom onset; and-~ 3. Had definite ECG changes indicating STEMI: persistent ST-elevation (≥0.2mV in two contiguous precordial leads, or ≥0.1mV in at least two limb leads), or new left bundle branch block, or ECG changes indicating true posterior MI.~* Written informed consent~* Able to be randomized within 24 hours of symptom onset~Exclusion Criteria:~* Age \<21 years.~* Was currently receiving an oral anticoagulant agent with an INR \>1.8.~* Had any contraindication to anticoagulation therapy such as high risk of bleeding or active bleeding.~* Had hemorrhagic stroke within the last 12 months.~* Had an indication for anticoagulation other than ACS.~* Pregnant women or women of child-bearing potential who were not using an effective method of contraception.~* Had a co-morbid condition with a life-expectancy \<6 months.~* Previous enrollment in one of the fondaparinux ACS trials.~* Participation in another pharmacotherapeutic study within the prior 30 days or was currently receiving an experimental pharmacological agent.~* Had a known allergy to heparin or fondaparinux.~* Had severe renal insufficiency (i.e. serum creatinine ≥3mg/dL or ≥265μmol/L).~* Had \>5000IU UFH administered prior to randomization.~* Had LMWH administered prior to randomization.~* Subject had pre-randomization revascularization (PCI) for the index event.~* Subject had pre-randomization rescue PCI.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fondaparinux - UFH not indicated (Type: EXPERIMENTAL): Subjects with no indication for UFH therapy: 2.5mg od, sc, (1st dose IV) x 8 days or discharge
- Control - UFH not indicated (Type: PLACEBO_COMPARATOR): Subjects with no indication for UFH therapy: Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
- Fondaparinux - UFH indicated (Type: EXPERIMENTAL): Subjects indicated for UFH: 2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus + 24-48 hr infusion
- Control - unfractionated heparin (Type: ACTIVE_COMPARATOR): Subjects indicated for UFH: UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge

Based on this trial design, predict the completion outcome and termination type (if applicable).